China Meheco Group Co., Ltd.

600056

CNE000000Q29

China Meheco Group Co., Ltd. is mainly engaged in the operation of industrial pharmaceutical, commercial pharmaceutical and international trading businesses. Industrial Pharmaceutical segment mainly involves in the manufacture and distribution of chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, herbal decoction pieces and other pharmaceutical products. Commercial Pharmaceutical segment is mainly engaged in the wholesale and distribution of pharmaceuticals and medical devices. Trading segment is mainly engaged in the international exporting business and medical resourcing introduction.

Employees

8,389

Sector

Pharmaceuticals

Calendar

2024-10-27 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Shanghai S.E. Other stock markets 2024-09-13			5-day change	1st Jan Change
9.700 ^CNY	-1.12%		-3.29%	-13.16%

Sep. 13	Meheco Group Unit Gets China Nod for Herpes Drug	MT
Aug. 30	China Meheco's Unit Gets Nod to Add Specification for Ampicillin Sodium and Sulbactam Sodium for Injection	MT

Meheco Group Unit Gets China Nod for Herpes Drug	Sep. 13	MT
China Meheco's Unit Gets Nod to Add Specification for Ampicillin Sodium and Sulbactam Sodium for Injection	Aug. 30	MT
China Meheco Group's H1 Attributable Profit Falls 40% on Lower Revenue	Aug. 20	MT
China Meheco Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 20	CI
China Accepts Meheco Group's Active Pharmaceutical Ingredient Application for Premature Ejaculation Drug; Shares Fall 3%	Aug. 12	MT
China Meheco Unit's Cefuroxime Sodium Injection Passes Drug Regulator's Evaluation	Aug. 09	MT
China Meheco Group Co., Ltd.(SHSE:600056) dropped from SSE 180 Index	Jun. 13	CI
China Meheco Group Co., Ltd.(SHSE:600056) dropped from Shanghai Stock Exchange 180 Value Index	Jun. 13	CI
China Approves Meheco Unit's Supplementary Drug Application for Ear Disorder Medication	Jun. 12	MT
China Meheco Group Chairman, Vice Chairman Resign	May. 15	MT
China Meheco Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
China Meheco Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Meheco's Unit Gets Nod to Raise Specifications for Piperacillin Sodium for Injection	Feb. 20	MT
Argatroban Injection of Meheco's Subsidiary Passes Chinese Drug Regulator's Evaluation	Feb. 20	MT
Meheco's Unit Gets Nod to Market Peramivir Injection; Shares Down 4%	Feb. 05	MT
Meheco Unit's Antibiotic Passes Regulatory Evaluation in China	Jan. 24	MT
China Meheco Group Co., Ltd. agreed to acquire 46% stake in Hainan General Kangli Pharmaceutical Co., Ltd. from General Technology Group Pharmaceutical Holding, Ltd. for CNY 190 million.	Dec. 22	CI
Genertec Universal, Parent Form 2 Billion Yuan Fund	Dec. 22	MT
China Meheco’s Hypertension Drug Passes Generic Consistency Evaluation	Nov. 16	MT
China Meheco Group's Drugs Chosen for China's Centralized Drug Procurement	Nov. 08	MT
China Meheco Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
China Meheco Group Unit's Norfloxacin Capsules Passes Drug Regulator's Evaluation	23-10-13	MT
China Meheco’s Antibiotic Passes Generic Consistency Evaluation	23-10-04	MT
China Meheco Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
China Medicine Health Industry Gets Registration Certificate for Sitafloxacin Tablets	23-06-16	MT

China Meheco Group Co., Ltd.

Equities

600056

CNE000000Q29

Pharmaceuticals

Latest news about China Meheco Group Co., Ltd.

Chart China Meheco Group Co., Ltd.

Company Profile

Income Statement and Estimates